main content start

Homepage

Latest Videos

Latest Videos

Brightcove Home Latest Listing

Breast Cancer

Prostate Cancer

Multiple Myeloma

Multiple Myeloma

Brightcove Cards Listing

Popular on MedEnrich

Popular in No name
  • Myelodysplastic Syndromes8m 45s

    Current Challenges in MDS Diagnosis and Consequences

    Bone marrow examination-based diagnosis of MDS with either biopsy or aspirate remains standard of care but is associated with pain, bleeding, difficulty to use the same in elderly patients and hIgh interobserver variability.
    non invasive mds diagnosis web based mds diagnosis tools
  • Myelodysplastic Syndromes7m 3s

    Clinical Application of Web Based Tool for Improving MDS Diagnosis

    Gradient Based Model based on 10 routinely used parameters (Age, Gender, Hb, WBC, MCV, Platelets, Neutrophils, Monocytes, Glucose, Creatinine) is now available to facilitate non-invasive diagnosis of MDS.
    mds non-invasive diagnosis
  • Breast Cancer14m 46s

    ESMO 2022 Breast Cancer Comprehensive Coverage

    View comprehensive coverage of Breast Cancer from ESMO 2022
    dose dense adjuvant chemotherapy esmo keynote -522 monarch -3 study
  • Myelodysplastic Syndromes3m 18s

    Anemia of MDS

    Anemia is common feature of MDS with 90% patients having anemia at diagnosis or initial presentation. Anemia not only impacts quality of life but is also prognostic in nature.
    anemia mds transfusion dependence
  • Myelodysplastic Syndromes17m 59s

    Genomics of AML -Therapeutic and Prognostic Implications

    ~40% of AML patients have targetable mutations. Younger patients often have FLT3-ITD or FLT3- TKD mutation. Mutations IDH-1 , IDH-2 & t-53 mutations are more common in elderly patients.
    idh 1& 2 mutations flt3-tkd mutations bcl2 inhibtors genomics of aml
  • Multiple Myeloma3m 11s

    Tips on using Pomalidomide Based Regimens in Multiple Myeloma

    For relapsed and refractory multiple myeloma, use of pomalidomide often in combination with dexamethasone or other agents is recommended in patients who have failed at least two prior treatments, including lenalidomide and a proteasome inhibitor.
    clinical practice tips improved patient outcomes rrmm management pomalidomide
  • OncoSpecials2m 41s

    Low Dose Dasatinib Ready For Clinical Practice

    Several studies carried out by institutions of repute have shown that Dasatinib 50 mg is as effective as 100 mg with less side effects.
    low dose dasatinib dasatinib 50mg
  • Breast Cancer8m 46s

    Expert Perspective - How I Treat Metastatic Her2 Positive Breast Cancer

    Anti-HER2 directed therapy remains the cornerstone of care for individuals with HER2-positive metastatic breast cancer (MBC).
    anti-her2 directed therapy her2-positive metastatic breast cancer expert perspective algorithm for management of her2 positive mbc
  • Breast Cancer11m 14s

    Oral Selective Estrogen Receptor Degraders for ESR-1 Mutant Metastatic Breast Cancer

    Endocrine therapy is the mainstay in the management of patients with Hormone receptor positive (ER+ve) Metastatic Breast Cancer. Tumor progression in ER+ve MBC could be attributed to genomic alterations such as ESR mutations.
    biomarkers esr1 mutation fulvestrant hormone receptor positive mbc serd
  • Pharmacy37m 20s

    Quality management systems in pharmacy practice

    Dr Scott Soefje, PharmD, Mayo Clinic
    Provides a perspective “Quality Management Systems in Pharmacy Practice”.
    mednrich
  • For Pharmacist

    For Pharmacist

    Brightcove Cards Listing

    Webinars

    Webinar Cards Listing

    MedBytes

    MedBytes

    Medbytes Cards Listing
    Hi, can I help?
    Chat SupportX
    Support Team
    Hello, how can I help you today?
    Please select one of the below options.

    Find Information

    Unable to Login or Register

    Want to share feedback